Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14906773 | 0.87 | PDGFRB (0.54) | ALDH1A1NPC1RAB9AMAPTPDGFRB | |
| SCHEMBL14906805 | 0.86 | RAB9A (0.62) | ALDH1A1RAB9APDGFRBPDGFRACYP19A1 | |
| SCHEMBL17796892 | 0.83 | ALDH1A1 (0.69) | ALDH1A1NPC1RAB9AKMT2AMAPT | |
| SCHEMBL20557840 | 0.81 | NPC1 (0.66) | ALDH1A1NPC1RAB9AKMT2AMAPT | |
| SCHEMBL3204572 | 0.81 | CYP1A2 (0.68) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL14906661 | 0.80 | PDGFRB (0.48) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL7195157 | 0.79 | MMP2 (0.66) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL28167297 | 0.78 | PDGFRB (0.43) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL14906801 | 0.78 | MET (0.58) | MAPTPDGFRBPDGFRA | |
| SCHEMBL14906806 | 0.78 | PDGFRB (0.49) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039759-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2018-08-07 | — | — | US | disclosed |
| US-10039759-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2018-08-07 | — | — | US | disclosed |
| EP-2776397-B1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2017-11-29 | — | — | EP | disclosed |
| US-9439896-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2016-09-13 | — | — | US | disclosed |
| US-9439896-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2016-09-13 | — | — | US | disclosed |
| US-20140296236-A1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20140296236-A1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| WO-2013061074-A1 | QUINOLINES AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039759-B2 | Quinolines as FGFR kinase modulators | FGFR1, FGFR3, FGFR2 | ALDH1A1 1595/4885NPC1 2191/4885RAB9A 1335/4885 |
| US-20140296236-A1 | QUINOLINES AS FGFR KINASE MODULATORS | FGFR1, FGFR2, FGFR3 | ALDH1A1 1527/4885NPC1 2063/4885RAB9A 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.